Technology | 2022.02.23
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
CORAL GABLES, Fla., Feb. 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]abuse-potential-301488462.html
